Status:
NOT_YET_RECRUITING
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Lead Sponsor:
AstraZeneca
Conditions:
Severe Asthma
Eligibility:
All Genders
12+ years
Brief Summary
The objectives of this study are to describe the occurrence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma in South Korea.
Detailed Description
Primary objective(s): * To estimate the incidence proportion of adverse events (AEs), adverse drug reactions (ADR1s), serious adverse events (SAEs), serious adverse drug reaction (SADRs), unexpected2...
Eligibility Criteria
Inclusion
- Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
- Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Exclusion
- Other off-label indications according to the locally approved prescribing information
- Current participation in any interventional trial
Key Trial Info
Start Date :
November 28 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2029
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06998095
Start Date
November 28 2026
End Date
October 31 2029
Last Update
December 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.